 |
Catalyst Pharmaceutical Partners Initiates a Registration-Directed U.S. Phase II(b) Clinical Trial in Collaboration With The National Institute on Drug Abuse and Veteran's Administration Cooperative Studies Program
11/18/10
|
18.2 KB |
|
| |
CORAL GABLES, Fla., Nov. 18, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that in collaboration with the National Institute on Drug Abuse (NIDA) and the Veterans Administration (VA) Cooperative Studies Program, it has initiated a registration-directed U.S. Phase II(b) clinical trial of CPP-109 in pat...
|
|
Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial and Operational Results
11/16/10
|
20.8 KB |
|
| |
CORAL GABLES, Fla., Nov. 16, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial and operational results for the third quarter and nine months ended September 30, 2010. Highlights for the third quarter of 2010 and subsequent events include:
Reported positive results of CPP-115 no...
|
|
Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners' Scientific Advisory Board
11/15/10
|
14.5 KB |
|
| |
Dr. Silverman is the Inventor of Pfizer's $3 Billion Lyrica® and Catalyst's CPP-115
CORAL GABLES, Fla., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Richard B. Silverman, Ph.D. has joined its Scientific Advisory Board. Highly accomplished in medicinal chemistry and rational drug...
|
|
Catalyst Pharmaceutical Partners Awarded $488,958 in Grants for Its CPP-109 and CPP-115 Projects Under the Section 48D Therapeutic Discovery Program
11/01/10
|
12.2 KB |
|
| |
CORAL GABLES, Fla., Nov 1, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has been awarded a total of $488,958 in grants for two qualifying therapeutic projects under section 48D of the Internal Revenue Code.
Catalyst submitted two qualifying projects:
-- CPP...
|
|
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Safety and Efficacy Results for CPP-115
11/01/10
|
19.5 KB |
|
| |
Nov 1, 2010 (GlobeNewswire via COMTEX News Network) --
Significant Improvement in Retinal Safety vs. Vigabatrin
Results Support Completing IND Enabling Studies
Catalyst to Hold Conference Call at 8:30 am ET Today to Discuss Results
CORAL GABLES, Fla., November 1, 2010 (GLOBE NEWSWIRE) ---- Cataly...
|
|
Catalyst Pharmaceutical Partners, Inc. Granted Orphan-Drug Designation for CPP-115 for the Treatment of Infantile Spasms
09/21/10
|
14.5 KB |
|
| |
CORAL GABLES, Fla., Sep 21, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Adm...
|
|
Catalyst Pharmaceutical Partners Announces Second Quarter 2010 Financial Results
08/13/10
|
19.1 KB |
|
| |
CORAL GABLES, Fla., Aug 13, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the second quarter and six months ended June 30, 2010.
Second Quarter 2010 Results
The Company reported a net loss of $1,328,541, or $0.07 per basic and diluted share, com...
|
|
Catalyst Pharmaceutical Partners, Inc. Raises $1.5 Million in Registered Direct Offering
08/06/10
|
13.8 KB |
|
| |
CORAL GABLES, Fla., Aug 6, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has entered into definitive agreements to sell 1,351,352 shares of its common stock at a price per share of $1.11 pursuant to a registered direct offering to two large mutual funds, representing gro...
|
|
European Patent Office Grants Patent for the Use of Vigabatrin/CPP-109 for the Prevention of Addiction to Opioids in Pain Management
07/09/10
|
14.2 KB |
|
| |
CORAL GABLES, Fla., Jul 9, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opio...
|
|
Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting
06/09/10
|
11.6 KB |
|
| |
CORAL GABLES, Fla., June 9, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Tuesday, June 15th at 5:20pm local time, Charles Gorodetzky, MD, PhD will deliver a presentation entitled "Vigabatrin for the treatment of stimulant dependence" at the College on Problems of Drug Dep...
|
|
Catalyst Pharmaceutical Partners Announces First Quarter 2010 Financial Results
05/18/10
|
17.2 KB |
|
| |
CORAL GABLES, Fla., May 18, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per...
|
|
Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
05/07/10
|
11.2 KB |
|
| |
CORAL GABLES, Fla., May 7, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that Jack Weinstein, Catalyst's Chief Financial Officer, will be making a presentation at the MoneyShow Conference to be held May 10th through May 13th at Caesars Palace in Las Vegas. Catalyst will present a Cor...
|
|
Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
04/26/10
|
11.3 KB |
|
| |
CORAL GABLES, Fla., April 26, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capi...
|
|
Catalyst Pharmaceutical Partners Signs Definitive Agreement With the National Institute on Drug Abuse To Conduct U.S. Phase II(B) Clinical Trial for Cocaine Addiction
04/13/10
|
13.3 KB |
|
| |
CORAL GABLES, Fla., April 13, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formula...
|
|
CPP-109 Clinical Trial Data to be Presented at the American Society of Addiction Medicine Annual Medical-Scientific Conference
04/09/10
|
11.8 KB |
|
| |
CORAL GABLES, Fla., April 9, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, ...
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2009 Financial Results
04/01/10
|
19.2 KB |
|
| |
CORAL GABLES, Fla., April 1, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter a...
|
|
Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
03/10/10
|
11.2 KB |
|
| |
CORAL GABLES, Fla., March 10, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held March 15th through March 17th at the Eden Roc Resort and Spa on Miami ...
|
|
Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
02/25/10
|
11.6 KB |
|
| |
CORAL GABLES, Fla., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco. For additional program inform...
|
|
Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction
02/23/10
|
13.1 KB |
|
| |
CORAL GABLES, Fla., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, fo...
|
|
Catalyst Pharmaceutical Partners to Discuss Development Plans for CPP-115 on February 23, 2010 Conference Call
02/22/10
|
18.7 KB |
|
| |
CORAL GABLES, Fla., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) will hold a conference call on Tuesday, February 23, 2010 to discuss its initial development plans for CPP-115. Patrick J. McEnany, Catalyst Pharmaceutical's Chief Executive Officer, will host the call.
CPP-115 is a compo...
|
|
|
Print